跳至主要内容
临床试验/EUCTR2020-000749-15-NL
EUCTR2020-000749-15-NL进行中(未招募)1 期

Resolution Enhancement by a Supplemental Open-Label Venoactive drug for Eight weeks in Deep Vein Thrombosis - The RESOLVE-DVT study

Academisch ziekenhuis Maastricht0 个研究点目标入组 44 人开始时间: 2020年5月18日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • ?Adult, defined as = 18 years of age
  • ?Objectively confirmed DVT by duplex echography
  • ?Proximal DVT, defined as an iliofemoropopliteal venous thrombosis
  • ?Acute DVT, defined as having symptoms for = 7 days at presentation
  • ?Willing and able to give written consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 44
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 44

排除标准

  • ?Previous DVT
  • ?Bilateral DVT, since the unaffected leg is needed as a reference for clinical signs
  • ?Pre-existent chronic venous insufficiency (CEAP-criteria C = 3), since this influences thrombus resolution
  • ?Active malignancy, inflammatory disease (e.g. rheumatoid arthritis) and/or immunosuppressive therapy, since this will influence circulating inflammatory biomarkers
  • ?Current pregnancy, since knowledge on the teratogenicity of the IMP is too limited
  • ?Indication for therapeutic thrombolysis, since this influences thrombus resolution
  • ?Contra-indication for DOAC, including reduced kidney function (eGFR < 30 ml/min/1,73 m2) and underweight (<50kg)

研究者

相似试验